Orexigen, which is developing treatments for central nervous system disorders, including obesity, filed for an IPO on Tuesday. Merrill Lynch is managing the deal. Terms and timing have yet to be announced.
Orexigen, which is developing treatments for central nervous system disorders, including obesity, filed for an IPO on Tuesday. Merrill Lynch is managing the deal. Terms and timing have yet to be announced.